Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunome Inc
(NQ:
IMNM
)
12.25
+0.05 (+0.41%)
Streaming Delayed Price
Updated: 3:23 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunome Inc
< Previous
1
2
3
4
5
6
Next >
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
October 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
October 18, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
October 11, 2024
Via
Benzinga
Evaluating Immunome: Insights From 4 Financial Analysts
May 31, 2024
Via
Benzinga
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
October 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 01, 2024
Via
Benzinga
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Stock Sees RS Rating Jump To 91
August 20, 2024
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
Via
Investor's Business Daily
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
August 12, 2024
IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
July 25, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Phil Tsai as Chief Technical Officer
June 27, 2024
From
Immunome, Inc.
Via
Business Wire
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
May 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
May 21, 2024
Via
Benzinga
Immunome Announces Completion of Purchase of Assets from Atreca
May 20, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
May 17, 2024
From
Immunome, Inc.
Via
Business Wire
IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024
May 14, 2024
IMNM stock results show that Immunome beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 2024 Bank of America Healthcare Conference
May 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Kinney Horn as Chief Business Officer
May 02, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Sandra M. Swain to Board of Directors
April 25, 2024
From
Immunome
Via
Business Wire
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
April 05, 2024
From
Immunome, Inc.
Via
Business Wire
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
March 28, 2024
IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
March 28, 2024
From
Immunome, Inc.
Via
Business Wire
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
March 28, 2024
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.
Via
Benzinga
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 26, 2024
From
Immunome, Inc.
Via
Business Wire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.